Improved Treatment Assessment for Prostate Cancer Patients, According to UCLA Researchers

Improved Treatment Assessment for Prostate Cancer Patients, According to UCLA Researchers
UCLA researchers recently found there is an increased use of radiotherapy in patients with indolent prostate cancer regardless of tumor biology. The results underpinned the need for improved treatment assessment. The study titled “Population-Based Assessment of Determining Treatments for Prostate Cancer,” was recently published in JAMA Oncology. Men with indolent prostate cancer frequently opt for either radical prostatectomy or radiotherapy. After treatment, these men may experience considerable adverse side effects. In the study, the researchers aimed to determine population-based predictors for treatment and use of watchful waiting or active surveillance in 37,621 men with indolent prostate cancer. Data was retrevied from the Surveillance, Epidemiology, and End Results (SEER)–Medicare from 2004 to 2007. All patients were then followed until 2009. Results showed that radiation therapy was the most common treatment (57.9%), followed by radical prostatectomy (19.1%), and other treatments including wait-and-see approach and active surveillance (9.6%). Using a logistic regression method, researchers found that patients and providers significantly integrate age and comorbidities when determining radical prostatectomy while regional variation and referral patterns influence the use of radiation therapy. Patient demographics and tumor characteristics significantly account for 40% of patients undergoing prostatectomy, 12% choosing watchful waiting or active surveillance and only 3% undergoing radiotherapy. “Doctors and patients view radiation as safe,” said Dr. Karim Chamie, assistant professor of urology. “There’s no anesthesia or hospitalization, the patient comes in for 15 or 20 minutes for their daily radiation treatment, it’s localized to
Subscribe or to access all post and page content.